drugset / Trial / NCT00711165

Mometasone and Markers of Airway Inflammation

NCT00711165

Phase 4 Completed 12 enrolled Creighton University Schering-Plough · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Timeline

Start
2005-08
Primary completion
2006-04
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mometasone furoate Other / unclassified 400 ug Inhaled

Indications